Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib, Open Label, Combination Study of Nintedanib With 5-Azacitidine in Acute Myeloid Leukemia Characterized by HOX Gene Overexpression, That Are Not Candidates of Intensive Chemotherapy

NCT03513484 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT03513484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03513484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib, Open Label, Combination Study of Nintedanib With 5-Azacitidine in Acute Myeloid Leukemia Characterized by HOX Gene Overexpression, That Are Not Candidates of Intensive Chemotherapy
Lead sponsor
Northwestern University
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 14, 2018
Completion date
January 31, 2027
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia with t(9;11)(p22.3;q23.3); mllt3-kmt2a, fibroblast growth factor basic form measurement, flt3 internal tandem duplication, recurrent adult acute myeloid leukemia, refractory acute myeloid leukemia